Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (DARWIN 1)

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 998-1008

  Westhovens, R ^a,b   Taylor, P C ^c   Alten, R ^d   Pavlova, D ^e   Enriquez Sosa F ^f   Mazur, M ^g   Greenwald, M ^h   Van Der Aa, A ⁱ   Vanhoutte, F ⁱ   Tasset, C ⁱ   Harrison, P ⁱ  

^a SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Schlosspark Klinik   (Germany)

^e LTD mandM CENTRS ^*  (Latvia)

^f CLINSTILE   (Mexico)

^g IMSP Institul de Cardiologie   (Moldova)

^h Desert Medical Advances   (United States)

ⁱ GALAPAGOS NV   (Belgium)

Author keywords

DAS28; Methotrexate; Rheumatoid Arthritis; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FILGOTINIB; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; JANUS KINASE 1; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DAS28; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; INFECTION; LYMPHOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; MULTICENTER STUDY; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SIDE EFFECT; SIMPLIFIED DISEASE ACTIVITY INDEX; THROMBOCYTE COUNT; TUBERCULOSIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISABILITY; METABOLISM; ORAL DRUG ADMINISTRATION; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HUMANS; INFECTION; JANUS KINASE 1; MALE; METHOTREXATE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TRIAZOLES;

EID: 85007236113     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210104     Document Type: Article

References (23)

1. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1-25.
2. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
3. Mok CC, Tsai WC, Chen DY, et al. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2016;16:201-11.
4. Tanaka Y. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J Biochem 2015;158:173-9.
5. Ruderman EM, Nola KM, Ferrell S, et al. Incorporating the treat-To-Target concept in rheumatoid arthritis. J Manag Care Pharm 2012;18:1-18.
6. Laurence A, Pesu M, Silvennoinen O, et al. JAK Kinases in health and disease: An update. Open Rheumatol J 2012;6:232-44.
7. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 5):v3-11.
8. Pfizer Inc. Xeljanz® (tofacitinib) prescribing information. Last revised Nov 2012.
9. Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs 2014;23:1067-77.
10. Namour F, Desrivot J, Van der Aa A, et al. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett 2016;10:38-48.
11. Galien R, Brys R, Van der Aa A, et al. Absence of effects of filgotinib on erythrocytes, CD8+ and NK Cells in rheumatoid arthritis patients brings further evidence for the JAK1 selectivity of filgotinib. ACR, 2015:2781.
12. Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191:3568-77.
13. Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of Phase IIB dose selection. Clin Pharmacokinet 2015;54:859-74.
14. Ongenaert M, Dupont S, Vayssière B, et al. Treatment of rheumatoid arthritis patients with the JAK1-selective inhibitor GLPG0634 reverses an arthritis-specific Blood Gene Signature to healthy state. ACR, 2014:1494.
15. Tasset C, Harrison P, van der Aa A, et al. The JAK1-selective inhibitor GLPG0634 is safe and rapidly reduces disease activity in patients with moderate to severe rheumatoid arthritis; results of a 4-week dose ranging study. ACR, 2013:2381.
16. Vanhoutte F, Mazur M. Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-Term treatment of rheumatoid arthritis; results of a phase IIA trial. EULAR, 2012:OP0263.
17. van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 2000;59(Suppl 1):i28-31.
18. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005;64:1582-7.
19. Notarangelo LD, Mella P, Jones A, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat 2001;18:255-63.
20. Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333-40.
21. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
22. Park SO, Wamsley HL, Bae K, et al. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS ONE 2013;8:e59675.
23. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-Tumor necrosis factor therapy. Arthritis Care Res (Hoboken) 2012;64:1282-91.